Where is Aurora Pharmaceutical headquartered?

Aurinia Pharmaceuticals is recorded with headquarters in northfield, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Aurora Pharmaceutical publicly traded?

Yes — Aurora Pharmaceutical is listed as a public company with ticker AUPH on NYSE in SEC EDGAR-derived records.

What drugs are associated with Aurora Pharmaceutical?

We link 1 drug profile(s) where Aurora Pharmaceutical appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Aurora Pharmaceutical sponsoring?

Aurora Pharmaceutical is linked to 14 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Aurora Pharmaceutical as applicant?

7 USPTO PatentsView record(s) name Aurinia Pharmaceuticals or a normalized variant as applicant.

What pipeline phases does Aurora Pharmaceutical have in our database?

Phase distribution from linked programs: phase 2: 7, phase 3: 5, phase 1: 2.

How many US-approved drugs are linked to Aurora Pharmaceutical?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Aurora Pharmaceutical hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Aurora Pharmaceutical?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Aurora Pharmaceutical data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Aurinia Pharmaceuticals Pharmaceuticals Company Profile

Name: Aurinia Pharmaceuticals intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 1196 Hwy 3 South, Northfield, MN 55057, US
Founded: 2007
Employees: 81
Programs: 14
Drugs: 10
Patents: 7

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Aurora Pharmaceutical is a pharma organization headquartered in northfield, USA. It trades on NYSE under ticker AUPH. Primary therapeutic focus areas include Lupus Nephritis, Generalized Myasthenia Gravis, Dry Eye Syndrome, Myasthenia Gravis, Generalized, Drug-drug Interaction. NovaPharmaNews links 14 clinical program(s), 1 drug profile(s), and 7 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (7), phase 3 (5), phase 1 (2).

Company snapshot

Aurora Pharmaceutical is an American manufacturer of quality veterinary pharmaceutical products chosen by professionals throughout the USA.

2 approved product(s) across US/EU regulatory metadata.
14 active pipeline program(s) linked via ClinicalTrials.gov.
7 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Aurinia Pharmaceuticals. Not investment advice.

Top assets

View drugs (10) View projects (14)

Lead pipeline drugs

acetic acid, glacial
approved
dose
Marketed / approved
high-dose
Marketed / approved
octreotide
Marketed / approved

Active clinical programs

0.05% Voclosporin Ophthalmic Solution (VOS) Dry Eye Syndrome
Phase 3
Voclosporin Lupus Nephritis
Phase 3
Voclosporin Adolescent Lupus Nephritis
Phase 3
voclosporin Psoriasis
Phase 3

Momentum

Proprietary activity score for Aurinia Pharmaceuticals.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 18 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Bristol Myers Squibb

TA overlap score 28
Peer + 0 momentum

Dianthus Therapeutics, Inc

TA overlap score 21.2

Recent activity

Latest pipeline, patent, and corporate events for Aurinia Pharmaceuticals.

Jun 8, 2026 Clinical update
AUR-200-2024-02 — Phase 2
Jun 8, 2026 Clinical update
voclosporin — Phase 3
Jun 8, 2026 Clinical update
Voclosporin Ophthalmic Solution — Phase 2
Jun 8, 2026 Clinical update
Voclosporin High Dose — Phase 2
Jun 8, 2026 Clinical update
Simvastatin — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Aurinia Pharmaceuticals?

Aurora Pharmaceutical is a pharma organization headquartered in northfield, USA. It trades on NYSE under ticker AUPH. Primary therapeutic focus areas include Lupus Nephritis, Generalized Myasthenia Gravis, Dry Eye Syndrome, Myasthenia Gravis, Generalized, Drug-drug Interaction. N
Is Aurinia Pharmaceuticals publicly traded?

Yes. Aurinia Pharmaceuticals is listed with ticker AUPH on NYSE per SEC EDGAR records linked on this profile.
What drugs does Aurinia Pharmaceuticals develop or market?

We link 10 drug profile(s) where Aurinia Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aurinia-pharmaceuticals#company-drugs.
What are the latest developments for Aurinia Pharmaceuticals?

In the last 12 months our linked public records show 14 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Aurinia Pharmaceuticals focus on?

Aurinia Pharmaceuticals focuses on Lupus Nephritis, Generalized Myasthenia Gravis, Dry Eye Syndrome based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others